Article info

Download PDFPDF
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Authors

  1. Correspondence to Dr Jyoti Mayadev, University of California San Diego, La Jolla, California 92093-0021, USA; jmayadev{at}ucsd.edu
View Full Text

Citation

Mayadev J, Zamarin D, Deng W, et al
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Publication history

  • Accepted December 3, 2019
  • First published December 22, 2019.
Online issue publication 
May 04, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.